CliffBio
small molecule

CICLOPIROX

CICLOPIROX

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameCICLOPIROX
Active ingredientCICLOPIROX
Strength8%
Dosage formSOLUTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalSeptember 2007
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.